Li D, Tan R, Hernandez S, Reilly N, Bussberg C, Mansfield C. Patient preferences for unresectable hepatocellular carcinoma treatments: a discrete-choice experiment. Cancers. 2023 Feb 25;15(5):1470. doi: 10.3390/cancers15051470
Strober B, Gottlieb AB, Sherif B, Mollon P, Gilloteau I, McLeod L, Fox T, Mordin M, Gnanasakthy A, Papavassilis C, Lebwohl MG. Secukinumab sustains early patient-reported outcome benefits through 1 year: results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept. J Am Acad Dermatol. 2017 Apr;76(4):655-61. doi: 10.1016/j.jaad.2016.11.043